Clinical Trial Update: HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC [Phase 2]

View source ↗

Summary

Phase 2 trial comparing HAIC+Lenvatinib+Tislelizumab to D-TACE+Lenvatinib+Tislelizumab for unresectable hepatocellular carcinoma is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Unresectable Hepatocellular Carcinoma

Drugs mentioned

• D-TACE
• HAIC (hepatic artery infusion chemotherapy)
• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Wen Li | Conditions: Unresectable Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN